Multiple Myeloma (MM) Clinical Trials

11 recruiting

Frequently Asked Questions

Common questions about Multiple Myeloma (MM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Multiple Myeloma (MM)
C4 Therapeutics, Inc.60 enrolled19 locationsNCT07280013
Recruiting
Phase 1Phase 2

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Not Applicable

CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)

Multiple Myeloma (MM)
Poitiers University Hospital60 enrolled1 locationNCT07342179
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple Myeloma (MM)
Sinocelltech Ltd.292 enrolled1 locationNCT07297329
Recruiting
Phase 2

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled9 locationsNCT06974786
Recruiting
Not Applicable

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

LymphomaLeukemiaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma+4 more
Medical University of Gdansk100 enrolled1 locationNCT07270263
Recruiting

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich208 enrolled2 locationsNCT07309497
Recruiting
Not Applicable

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

LeukaemiaLymphomaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Zhongnan Hospital196 enrolled1 locationNCT07305337
Recruiting
Early Phase 1

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07101705
Recruiting

Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers

Multiple Myeloma (MM)Hematologic Neoplasm
Azienda USL Reggio Emilia - IRCCS190 enrolled1 locationNCT07014865
Recruiting
Early Phase 1

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Anhui Provincial Hospital36 enrolled1 locationNCT07085559
Recruiting

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Multiple Myeloma (MM)Multiple Myeloma, Relapsed
Sung-Soo Park174 enrolled1 locationNCT07051850
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL)High Grade B-Cell Lymphoma, Not Otherwise SpecifiedMultiple Myeloma (MM)+3 more
IDP Discovery Pharma S.L.37 enrolled11 locationsNCT05908409
Recruiting

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Multiple Myeloma (MM)Chronic Lymphocytic Leukaemia (CLL)Secondary Immunodeficiency (SID)
Medical University Innsbruck120 enrolled5 locationsNCT06821880
Recruiting

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled4 locationsNCT06767254